Takeda proposes divestment of Shire GI candidate, announces loans

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it proposed to the European Commission a potential divestment of Crohn’s disease and ulcerative colitis candidate SHP647 once it

Read the full 259 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE